The authors thank the patient for permission to use his data and cooperating with this report. The American Society of Tropical Medicine and Hygiene has waived the Open Access fee for this article due to the ongoing COVID-19 pandemic and has assisted with publication expenses.
Office for the Coordination of Humanitarian Affairs Services, reliefweb , 2021. Coronavirus Disease (COVID-19): Weekly Epidemiological Update (24 August 2021). Available at: https://reliefweb.int/report/world/coronavirus-disease-covid-19-weekly-epidemiological-update-24-august-2021. Accessed February 11, 2022.
Mohammed AH , Blebil A , Dujaili J , Rasool-Hassan BA , 2020. The risk and impact of COVID-19 pandemic on immunosuppressed patients: cancer, HIV, and solid organ transplant recipients. AIDS Rev 22: 151–157.
Otsuka Y , Kobayashi T , 2020. Case report: a patient with COVID-19 under myelosuppression induced by chemotherapy. Am J Trop Med Hyg 103: 1983–1985.
Strangfeld A et al.2021. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 80: 930–942.
Vasconcelos J , Portugal R , Torres R , Falcao S , 2021. Intravenous immunoglobulin as a therapeutic option for patients with worsening COVID-19 under rituximab. BMJ Case Rep 14: e243338.
Tudesq J-J et al.2018. Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders. Autoimmun Rev 17: 115–124.
Hoffmann MS , Siddhartha G , 2021. Delayed COVID-19 respiratory failure in patients with lymphoma on rituximab-based chemoimmunotherapy. Clin Lymphoma Myeloma Leuk 21: e548–e550.
Pierpont TM , Limper CB , Richards KL , 2018. Past, present, and future of rituximab: the world’s first oncology monoclonal antibody therapy. Front Oncol 8: 163.
Regazzi MB et al.2005. Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Ther Drug Monit 27: 785–792.
Marco H et al.2014. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord 15: 178.
Tzilas V , Manali E , Papiris S , Bouros D , 2020. Intravenous immunoglobulin for the treatment of COVID-19: a promising tool. Respiration 99: 1087–1089.
Leandro MJ , Cambridge G , Ehrenstein MR , Edwards JC , 2006. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with RA. Arthritis Rheum 54: 613–620.
Leandro MJ , Cambridge G , Edwards JC , Ehrenstein MR , Isenberg DA , 2005. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 44: 1542–1545.
Leipe J , Wilke EL , Ebert MP , Teufel A , Reindl W , 2020. Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab. Semin Arthritis Rheum 50: 1087–1088.
Guilpain P et al.2021. Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia. Ann Rheum Dis 80: e10.
Avouac J , Airó P , Carlier N , Matucci-Cerinic M , Allanore Y , 2021. Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab. Ann Rheum Dis 80: e37.
Wright Z , Bersabe A , Eden R , Bradley J , Cap A , 2021. Successful use of COVID-19 convalescent plasma in a patient recently treated for follicular lymphoma. Clin Lymphoma Myeloma Leuk 21: 66–68.
Vasconcelos J , Portugal R , Torres R , 2021. Intravenous immunoglobulin as a therapeutic option for patients with worsening COVID-19 under rituximab. BMJ Case Rep 14: e243338.
Tepasse PR et al.2020. Persisting SARS-CoV-2 viremia after rituximab therapy: two cases with fatal outcome and a review of literature. Br J Haematol 190: 185–188.
Hoon Baang J et al.2021. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis 223: 23–27.